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Combretastatin A4-phosphate (CA4P) is an anti-vascular agent which selectively shuts down blood 
supply in tumours, resulting in extensive tumour necrosis. The aim of this study was to assess in vivo, 
non-invasive ultrasound techniques for the early evaluation of tumour perfusion following CA4P 
treatment of spontaneous tumours. Eight dogs that bore spontaneous tumours were enrolled and were 
subsequently treated with a single dose of intravenous CA4P. Perfusion of tumours was evaluated by 
power Doppler ultrasound (PDUS) pre-treatment (0 h), during the injection (10 min, 20 min, 30 min) and 
after CA4P infusion (24 and 72 h). Vascularity index (VI) of the tumour tissue was quantitatively analysed 
and accuracy was verified by correlation analysis with the results of immunohistochemical evaluation 
of microvessel density (MVD). Central and peripheral perfusion was evaluated by contrast-enhanced 
ultrasound (CEUS) pre-treatment and at 72 h post-treatment. Post-treatment, PDUS demonstrated a 
significant decrease in VI within 10 min of CA4P infusion. CEUS parameters demonstrated a significant 
decrease in blood velocity and volume in the central aspect of the tumour. Histology revealed a 4.4-fold 
reduction (p < 0.001, 95% CI [2.2,9.4]) in MVD and a 4.1-fold increase (p = 0.003, 95% CI [1.4,11.8]) in 
necrotic tumour tissue. A strong correlation between PDUS results and immunohistochemical results 
was found (Pearson R2 = 0.957, p < 0.001). Furthermore, the findings of PDUS were supported by 
the objective results of the CEUS analyses. These data suggest a role for ultrasound in real-time, non-
invasive monitoring of tumour vascular response as an early indicator of CA4P treatment efficacy.
Tumour vasculature is crucial for survival, growth, and spread of tumours and is a promising pharmacological 
target in anti-cancer strategies1,2. Vascular targeting exploits the morphological differences between tumour and 
normal vasculature3–9. Whereas antiangiogenic agents (AAA’s) prevent formation of new blood vessels, vascular 
disrupting agents (VDA’s) destroy the tumour neovasculature10,11.
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Combretastatin A4-phosphate (CA4P) is the best known VDA. It depolymerizes the microtubules of imma-
ture vessel endothelial cells, inducing vessel occlusion and resulting in shutdown of tumour perfusion within 
an hour of administration6,12,13. This drug has been subjected to a range of combined-therapy trials, including 
surgery, anti-angiogenic therapy, chemotherapy, and radiotherapy14–21. Considering the success of anti-vascular 
therapies and their future prospects, efficient screening methods of treatment response are highly sought-after.
The gold standard to assess the therapeutic effect of anti-vascular therapy on tumour vascularisation is immu-
nohistochemical determination of microvessel density (MVD) (maximal number of blood vessels per unit area 
of section) in pre- and post-treatment surgical biopsies22. Given the invasive nature of sequential biopsies and the 
repeated need for anaesthesia, immunohistochemical MVD assessment has limited utility in a clinical setting. 
Thus, there is a clinical interest in non-invasive yet accurate imaging techniques that allow serial assessment of 
tumour perfusion in situ, enabling visualization of therapy response.
Current non-invasive imaging modalities to effectively evaluate the vascular response to CA4P and other VDA’s 
in rodents, rabbits, and men include dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)23–28, 
diffusion-weighted imaging25,29, perfusion computed tomography30, positron emission tomography (PET)31, biolu-
minescence imaging (BLI)26,28,32,33, photoacoustic imaging (PAI)34,35, and dynamic contrast-enhanced (DyCE) fluo-
rescent imaging36. Recently, contrast-enhanced ultrasound (CEUS) assessment in tumour-bearing mice was added to 
this list26,37–39. Power Doppler ultrasound (PDUS) has been used to assess vascularity in a range of animal and human 
tumours22,40–43 and for detection of blood flow changes following anti-vascular treatment32,44–46. It was recently found 
to be a reliable technique for the in vivo assessment of tumour angiogenesis41, but it has not yet been evaluated if this 
modality can be used as a reliable, non-invasive alternative to biopsies to asses CA4P treatment response. Considering 
that CA4P has been shown to reduce tumour blood flow within the first hour of therapy, well before vessels can regress, 
PDUS might provide a more veracious assessment of early response than immunohistochemistry.
In this study, we performed PDUS to assess the vascularity index (VI) before, during, and after a single dose 
of intravenous CA4P in a variety of spontaneous superficial solid tumours in dogs. Additionally, we used CEUS 
to quantitatively evaluate the intratumoural perfusion, both in the central and peripheral regions of the tumours. 
To verify the accuracy of PDUS, a correlation analysis was performed on the PDUS results and the results of con-
ventional MVD determined by immunohistochemistry, at 72 h post-treatment.
The aim of this work was to conduct a proof-of-principle study to assess the feasibility of using PDUS and 
CEUS as methods for assessing early tumour vascular inhibition by CA4P in clinical studies involving spontane-
ous, superficial solid tumours.
Results
Patient characteristics. Eight dogs entered the study. Baseline characteristics of participating patients are 
summarized in Table 1 and are further described elsewhere45. The study cohort consisted of four males and four 
females, belonging to six different breeds, and included five mesenchymal tumours, two epithelial tumours, and 
one round-cell tumour.
Tumour vascularity as assessed by power Doppler ultrasound. Pre-treatment (pre-CA4P), there 
appeared to be a marked variability in the tumour perfusion as evaluated by PDUS (Table 2). The sarcomas were 
less well vascularized pre-treatment than the carcinomas and the mastocytoma. After 10 min of CA4P infusion, 
an overall significant decrease in VI was measured (p = 0.039) (Fig. 1). Although not every VI continued to 
decrease to the same extent, and three VI’s even demonstrated a slight increase between 24 and 72 h post-infusion 
(PI), overall the decrease in VI remained significant until 72 h PI.
Quantitative analysis of contrast-enhanced ultrasound. Tumour perfusion parameters assessed by 
CEUS also revealed the sarcomas to be less well vascularized pre-treatment than the carcinomas and the masto-
cytoma (Table 2). A difference in blood flow parameters of the tumour centre was evident in all tumour types after 
CA4P administration (Figs 2–4). Overall, a significant decrease in tumour blood volume [characterized by the peak 
enhancement (PE) (p = 0.001) and wash-in area-under-curve (WiAUC) (p = 0.001)] was observed after CA4P 
administration. Furthermore, a significantly slower blood flow velocity [characterized by the time to peak (TTP) 
(p = 0.003) and rise time (RT) (p = 0.006)] were present. Additionally, a significant increase (p = 0.019) of the resi-
dence time of blood in the tumour [characterized by the mean transit time (mTT)] was noted. Interestingly, blood 
flow parameters at the tumour periphery did not significantly alter after treatment in any of the dogs.
Dog n° Characteristics (breed, sex, age, weight) Tumour type, localization, size
1 Mixed breed, F, 7.5 y, 13 kg Adenocarcinoma, mammary gland, 30.2 cm3
2 American Staffordshire, Mn, 14.1 y, 36 kg Soft tissue sarcoma, right carpus, 252.7 cm3
3 Golden Retriever, Mn, 10.7 y, 31 kg Chondrosarcoma, left elbow, 339.6 cm3
4 Münsterlander, Fn, 4.8 y, 21 kg Soft tissue sarcoma, perineal, 897.2 cm3
5 American Staffordshire, Mn, 10.0 y, 38 kg Mastocytoma, left carpus, 112.5 cm3
6 Whippet, Fn, 7.8 y, 13 kg Soft tissue sarcoma, right carpus, 0.6 cm3
7 Mixed breed, F, 8.4 y, 12 kg Adenocarcinoma, mammary gland, 0.7 cm3
8 Bernese mountain dog, Mn, 7.5 y, 38 kg Histiocytic sarcoma, facial, 25.0 cm3
Table 1. Patient characteristics and tumour type of the dogs treated with combretastatin A4-phosphate. 
Abbreviations: F, Female; Fn, Female neutered; M, Male; Mn, Male neutered; y: age in years.
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Dog n°,  
tumour type
PDUS CEUS Histology
Vascularity Index (Vessels tumour area−1) CEUS Parameters (Central tumour in vivo)
Necrotic tumoural tissue 
(Necrosis tumour area−1)
Microvessel density 
(Vessels tumour area−1)
(In vivo) PE (au) WiAUC (au) TTP (s) RT (s) mTT (s) (Ex vivo) (Ex vivo)
base 10 min 20 min 30 min 24 h 72 h Base 72 h Base 72 h Base 72 h Base 72 h Base 72 h base 72 h base 72 h
1, C 0.48 0.37 0.23 0.14 0.10 0.04 3536 229 11553 2618 15.22 50.29 8.84 15.98 52.92 110.78 0.015 0.110 0.54 0.03
2, S 0.17 0.11 0.09 0.09 0.04 0.07 3247 1021 15600 8340 18.38 31.82 7.87 14.74 30.09 64.05 0.001 0.215 0.21 0.06
3, S 0.15 0.12 0.06 0.03 0.03 0.03 14 1 91 3 16.89 18.00 7.66 11.22 6.60 51.96 0.012 0.853 0.09 0.02
4, S 0.04 0.04 0.03 0.01 0.02 0.01 1357 610 4933 2760 14.27 16.53 5.90 7.34 32.37 50.06 0.013 0.023 0.03 0.02
5, M 0.26 0.23 0.16 0.20 0.20 0.24 2535 363 19967 1657 20.08 31.15 3.58 17.51 31.79 60.17 0.009 0.014 0.27 0.24
6, S 0.23 0.20 0.21 0.19 0.16 0.20 2170 2757 12940 25567 24.13 23.73 9.46 10.06 34.99 36.12 0.180 0.110 0.22 0.19
7, C 0.30 0.28 0.23 0.18 0.09 0.04 5407 3953 24967 20033 22.05 20.09 11.95 8.17 49.37 48.55 0.027 0.613 0.29 0.02
8, S 0.19 0.17 0.13 0.12 0.10 0.05 396 68 1374 185 19.40 38.21 3.52 9.18 52.50 61.41 0.158 0.404 0.20 0.06
Table 2. Vascularity index and CEUS parameters in vivo, and the relative amount of necrotic tumoural tissue 
and microvessel density ex vivo, pre-treatment and 72 hours after intravenous CA4P administration (75 mg m−2) 
in dogs with cancer Abbreviations: CEUS, Contrast-enhanced ultrasound; CA4P, Combretastatin A4-
phosphate; PDUS, Power Doppler ultrasound; PE, Peak enhancement; AU, Arbitrary unit, WiAUC, Wash-in 
area-under-curve; TTP, Time to peak; RT, Rise time; mTT, Mean transit time; C, Carcinoma; S, Sarcoma; M, 
Mastocytoma.
Figure 1. Tumour vascularization as measured by power Doppler ultrasound of a mammary gland 
adenocarcinoma (dog 1). (A) before intravenous CA4P treatment, (B) 24 h after treatment, (C) 72 h after 
treatment at matched locations. A decrease in central tumour vascularization is clearly noticeable (Scale 
bar = 3 cm).
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Figure 2. Tumour evaluation after CA4P treatment using contrast-enhanced ultrasound (CEUS) of a 
mammary gland adenocarcinoma at a matched location (dog 1). The left side of the image corresponds to the 
CEUS image of the tumour, the right side to the B-mode ultrasound. (A) before intravenous CA4P treatment, 
(B) 24 h after treatment. There is a large diffuse uptake of microbubble contrast throughout the entire tumour 
before treatment. In contrast, 24 h after treatment, uptake of microbubble contrast has greatly diminished in the 
central tumour, indicating a decrease in central tumour vascularization (Scale bar = 3 cm).
Figure 3. Regions of interest were manually drawn on the contrast-enhanced ultrasound (CEUS) image of 
Fig. 2: Yellow encompasses the entire tumour, green outlines the peripheral one-third radius, and magenta 
contains the centre two-thirds radius of the tumour. (C) Before intravenous CA4P treatment, (D) 24 h after 
treatment (Scale bar = 3 cm).
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Histopathological assessment of tumour necrosis and microvessel density. Pre-treatment and 
post-CA4P results for all patients are listed in Table 2.
Areas of necrosis were characterized by loss of tissue architecture, eosinophilic cellular debris, pyknosis of 
nuclei and/or nuclear fragmentation. The estimated overall ratio for necrosis was 0.08 (95% CI [0.02 to 0.19]) 
before treatment and 0.33 (95% CI [0.01 to 0.82]) 72 h after treatment, corresponding to an overall 4.1-fold 
increase in necrosis of the tumour after a single dose of CA4P (p = 0.003, 95% CI [1.39 to 11.81]). Several tumours 
demonstrated a heterogeneous response within one biopsy sample. Areas of necrotic cells were interspersed with 
areas of mitotic cells. In some tumours, large areas of the tumour had undergone complete cellular degeneration 
and only a few viable cells remained. These viable cells were arranged concentrically around the remaining patent 
blood vessels. In contrast, vessels that were blocked, resulting in complete vascular occlusion, were surrounded 
by necrotic tumour cells. The endothelial cells of these obstructed vessels were fragmented and in several of the 
blocked tumour vessels, thrombi were observed. (Fig. 5).
Concerning the MVD, the sarcomas demonstrated a lower MVD pre-treatment than the carcinomas and the 
mastocytoma, supporting the CEUS and PDUS findings. The number of tumour microvessels, identified by the 
von-Willebrand factor (vWF) staining, was observed to have decreased significantly 72 h after treatment (Fig. 6). 
The estimated ratio of MVD was 0.22 (95% CI [0.09 to 0.36]) pre-treatment versus 0.05 (95% CI [0.03 to 0.08]) 
post-treatment, corresponding to a 4.4-fold reduction (p < 0.001, 95% CI [2.23 to 9.39]) in tumour microvessels 
72 h after a single dose of CA4P.
Figure 4. Tumour evaluation after CA4P treatment of a mastocytoma using contrast-enhanced ultrasound 
(CEUS) of 3 regions of interest (ROI) (dog 5). Time-intensity curves of ROIwhole (yellow), ROIperiphery (green), 
and ROIcentre (magenta). (A) before treatment, (B) 72 h after treatment. An obvious decrease in tumour 
vascularization is noted by CEUS in all three ROI’s, but is most prominent in tumour centre.
Figure 5. Histopathological section of the central part of a chondrosarcoma (dog 3), 72 h after intravenous 
CA4P administration. The vessel has been obstructed by a thrombus (asterisk) and necrosis of the endothelial 
cell lining (arrowheads) is visible (Haemotoxylin and Eosin. Scale bar = 50 µm).
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Correlation of ultrasound parameters with (immuno)histopathological findings. For both the 
treated and pre-treated dogs, correlations between PDUS and MVD and between CEUS and MVD are illustrated 
in Fig. 7. Power Doppler ultrasound was highly correlated with the MVD determinations on the anti vWF stain-
ing (Pearson R2 = 0.957, p < 0.001). There was no significant correlation between any of the CEUS parameters 
and the MVD: PE (R2 = 0.397, p = 0.33), WiAUC (R2 = −0.166, p = 0.695), TTP (R2 = −0.217, p = 0.605), RT 
(R2 = 0.395, p = 0.333), and mTT (R2 = 0.078, p = 0.854).
Discussion
In this study, PDUS was compared with histopathology and assessed as a technique for the in vivo assessment of 
spontaneous tumour vascular response to CA4P treatment. Additionally, the reduction in tumour blood velocity 
was assessed by means of CEUS. Power Doppler ultrasound (US), CEUS and histopathology each revealed vas-
cular shutdown with considerable necrosis within a 72 h period post-treatment.
Ideally, clinical monitoring tools should be non-invasive, allowing for serial assessments of the same tumour 
mass without risk for the patient. Currently, the gold standard to assess the therapeutic effect of anti-vascular 
therapy on tumour vascularisation is microscopic determination of MVD in pre- and post-treatment histologi-
cal tissue sections22. To improve blood vessel detection on histological slides, immunohistochemical staining of 
endothelial cell markers is performed. However, in addition to tissue biopsy being an invasive monitoring tech-
nique, early treatment response of anti-vascular agents such as CA4P can be misjudged in post-treatment biop-
sies; as several VDA’s induce changes in tumour blood perfusion well before vessel regression becomes apparent 
on histopathological tissue sections22.
The need for non-invasive techniques allowing early evaluation of clinical patients treated with fast-acting 
anti-vascular treatments is evident. To date, non-invasive techniques such as DCE-MRI, PET, and near-infrared 
spectroscopy have been explored to demonstrate changes in tumour perfusion and viability in both rodent 
tumour models and human patients13,23,27,47. However, these techniques are not always readily available and they 
are expensive, and some require ionizing radiation (PET) and/or heavy sedation or even general anaesthesia of 
the patient (DCE-MRI, PET). In contrast, US is assumed to be a promising angiogenesis assessment modality, as 
it is a widely available, non-radioactive, real-time and cost-effective alternative for above-mentioned techniques39. 
Additionally, CEUS is also suitable for use in patients with renal and hepatic failure because of the pulmonary 
elimination of the contrast agent48.
Figure 6. Microvessel density counting in a mammary gland adenocarcinoma (dog 7), (A) Two weeks before 
CA4P treatment, (B) 72 h after CA4P treatment. A decrease in microvessel density is clearly noticeable (Anti-
von Willebrand Factor. Scale bar = 100 µm).
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Vascular imaging such as US allows quantification of the number and spacing of blood vessels and to assess 
blood flow in a non-invasive and functionally relevant way. Therefore, US has the potential to assess the immedi-
ate efficacy of anti-vascular therapy49. Power Doppler US is a technique that displays the strength of the amplitude 
in colour, rather than speed or direction information, by using the amplitude of a Doppler shift to detect moving 
matter50. Noise is assigned a uniform colour that remains constant while flow is shown as a contrasting colour. As 
a result, PDUS has three to five times the sensitivity of conventional colour Doppler for the detection of flow50,51. 
Although the sensitivity of the technique certainly varies with both vessel calibre and flow rate, previous studies 
have demonstrated Doppler detection of flow through tumour vessels as small as 10–20 μm52,53.
The results of the PDUS clearly confirmed that CA4P treatment of spontaneous solid tumours in dogs resulted 
in an acute tumour vascular response within 10 min after start of the infusion. The statistically significant corre-
lation between intratumoural VI and the gold standard MVD at 72 h supports the hypothesis that PDUS offers 
an objective and reliable assessment of the tumour vascularity at the time of US scanning in an in vivo and in situ 
manner22,41,43,44. Standardized power Doppler settings and image-processing protocols enable a precise and objec-
tive evaluation of the VI and make PDUS a convenient and immediately applicable way to determine the efficacy 
of anti-vascular agents in a therapeutic setting.
The susceptibility of PDUS to flash artefacts, because of its high motion sensitivity, is one of its major limi-
tations. Patient cooperation is necessary to decrease artefacts resulting from excessive movement (e.g. panting), 
as prominent soft-tissue motion may preclude the use of PDUS. For human patients, this is not likely to form 
a problem; veterinary patients may need sedation with drugs known not to interfere with vascularisation (i.e. 
Butorphanol, MSD, Brussel, Belgium)54 if highly excited or fearful.
The CEUS contrast agent SonoVueTM consists of sulfur hexafluoride-filled microbubbels (MB’s) in a phospho-
lipid shell48. The mean diameter of the sulfur hexafluoride-filled MB’s is 2.5 µm, resulting in a strictly intravascular 
trajectory of the bubbles without any interstitial component55. At low acoustic power, alternating expansion and 
contraction of the MB’s result in a vibration, generating harmonic echoes. The harmonic signal produced by the 
MB’s is greater than that of the surrounding tissue, making CEUS a very sensitive imaging technique, well suited 
for the evaluation of blood flow in functional vessels56.
After CA4P administration, all tumours demonstrated significant changes in the CEUS perfusion characteristics. 
Pre-treatment, CEUS demonstrated a rapid inflow of the MB’s into the entire tumour, a distinctive feature of malig-
nant tumours55,57, followed by a slow clearance. Post-treatment, the time constant for contrast to reach the tumour 
(TTP) was increased, likely indicating a less aggressive behaviour of the tumour after CA4P treatment. Together with 
a significant drop in tumour blood volume (PE and WiAUC) and increase in tumour transit time (RT and mTT), 
it is possible that CA4P treatment induced a slower tumour progression, despite a continued growth of the tumour 
if no adjuvant therapy is administered58. Of particular interest was that the software for analysis of the CEUS data 
allowed for an easy and objective distinction between the measurements of tumour centre versus periphery, which is 
important in the determination of drug efficacy and prognosis. Results post-CA4P-treatment clearly demonstrated 
a high susceptibility of the tumour centre to necrosis formation while the perfusion of the tumour periphery was 
consistently poorly affected, which is in accordance with previous research3,6,47,59.
Although the CEUS parameters demonstrated significant reduction in perfusion in the tumour centre, the 
correlation between the CEUS parameters and the gold standard MVD failed to reach statistical significance. In 
the study carried out by Zhang and colleagues39, the CEUS parameter maximum intensity (IMAX) was found 
to be closely correlated with MVD. This parameter represents the average US contrast agent concentration of 
the analysis region of interest (ROI) (tumour tissue) relative to that of the reference ROI (healthy tissue) which 
is assumed to be 100%. Calculating the IMAX necessitates obtaining images including both tumour tissue and 
healthy tissue in the same image. This is perfectly feasible in rodent tumour models, with tumours reaching only 
several mm’s in diameter. However, in pet animal or human patients with spontaneous tumours, which can easily 
reach several cm’s in diameter, it is not possible to obtain images containing both tumoural and healthy tissue. 
Additionally, for some tumours it can be difficult to distinguish healthy tissue from tumour infiltrated tissue, 
based on US alone. Therefore, IMAX is not always a useful parameter in a clinical setting. Notwithstanding the 
fact that the CEUS parameters assessed in the current research were not significantly correlated to the MVD 
results, previous research demonstrated that CEUS provides an excellent non-invasive quantitative and quali-
tative alternative for tissue biopsies, as it has proven to be at least as sensitive a method for tumour angiogenesis 
Figure 7. Scatter plot revealing the correlation between the power Doppler ultrasound (PDUS) and the 
microvessel density (R2 = 0.957; p < 0.001). The X- and Y-axes are expressed as the ratios between pre- and post 
CA4P measurements.
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monitoring as histopathology39,60. In this research, CEUS was not considered a reliable alternative, but rather an 
excellent adjunct to PDUS to assess tumour blood velocity between the different tumour areas before and after 
CA4P treatment. The necessity for intravenous administration and the availability of the MB’s and the dedicated 
software can be considered as drawbacks for the use of CEUS. However, the authors are of the opinion that the 
addition of CEUS to PDUS is relevant and beneficial, and the combination of these imaging modalities is an 
attractive and preferable alternative to sequential biopsies for the evaluation of CA4P treatment response.
There are some limitations to this clinical trial. Only a small number of patients with a variety of tumour types 
and stages were assessed. Additionally, only dogs with superficial tumours were enrolled in this proof-of-concept 
study because a superficial location made it practical and acceptable to obtain a 72 h post-treatment tumour 
biopsy. Lastly, due to ethical regulations, only tumoural tissue was biopsied and imaged by PDUS and CEUS, 
while healthy tissue was not evaluated. Therefore, it cannot be confirmed that the effect of CA4P was truly limited 
to tumoural tissue without healthy tissue being affected at all.
Conclusion
This research confirms that measurement of the intratumoural VI by means of PDUS is correlated highly with 
the conventional MVD assay and is potentially useful for clinical monitoring of CA4P treatment. Assessment of 
the CEUS parameters support these findings and additionally prove primary response location to be the tumour 
centre. Additionally, our results emphasize that dogs with spontaneous cancer offer a novel and relevant model 
for studies of vascular disrupting therapy.
Considering the US results of this study, the clinical value of this non-invasive modality warrants further 
exploration and development of this technology during assessment of vascular targeting therapies.
Methods
Dogs. Dogs with histopathologically confirmed, superficial and well-defined solid tumours, suitable for US 
examination, were enrolled. Specifications on patient selection have been described elsewhere45.
Approval was obtained from the local research Ethical Committee (approval no. EC2015/143 and EC2016/66) 
of the Faculty of Veterinary Medicine of Ghent University, Belgium and from the Deontological Committee of 
the Federal Public Service of Health, Food Chain Safety and Environment, Belgium. The study protocol adhered 
to the guidelines and regulations of the European Communities Council Directive (86/609/EEC)/principles of lab-
oratory animal care (NIH publication No. 85-23, revised 1985). Written informed consent was obtained from all 
Figure 8. A representative slide of microvessel density counting in a mammary gland adenocarcinoma (dog 7)  
before treatment with CA4P, before (A) and after (B) application of an H-DAB filter (Anti-von Willebrand 
Factor. Scale bar = 100 µm).
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patient owners before entry into the study. The use of CA4P in canine patients was approved (approval number 
0002588) by the Belgian Federal Agency for Medicines and Health Products (FAMHP).
Histologic tumour assessment. Pre-treatment tumour assessment consisted first of histopathological 
necrosis assessment and immunohistochemical MVD evaluation. A preliminary PDUS determined the imag-
ing plane with maximum tumour perfusion and subsequently, after patient sedation, at least dual 6-mm punch 
biopsies were taken in this region. Further evaluation by medical imaging was then postponed for a minimum of 
two weeks, to preclude any influence (i.e. presence of air or suture material in the tumour) caused by the biopsy 
taking. 72 h following the CA4P-treatment and after all other assessments were completed, 6-mm punch biopsies 
were taken in the vicinity of the pre-treatment biopsies.
Preparation and administration of sterile CA4P solutions. Specifications on the preparation and 
administration of CA4P have been described in our previous study45. Lyophilized CA4P (GMP quality) with 
a purity of >99% was purchased from Selleck Chemicals LLC (Houston, Texas, USA), and stored under light 
exclusion at a temperature of −20 °C. For the preparation of every personalized solution, the drug was accurately 
weighed (Mettler Toledo XS 204; readability 0.1 mg) and reconstituted in a sterile phosphate buffered saline (PBS) 
(Thermo Fisher Scientific, Erembodegem, Belgium) solution. Subsequently, the required volume of CA4P solu-
tion was pipetted and transferred to sterile amber vials. Finally, PBS was added until a final volume of 10 mL was 
reached. All CA4P solutions were prepared in a biological safety cabinet and were administered within 30 min of 
preparation as an intravenous infusion at a dose of 75 mg m−2 61, over a time span of 30 min using a volumetric 
pump.
Power Doppler ultrasound imaging. To obtain the PDUS images, a linear 12-5 MHz transducer was used 
on a dedicated ultrasound machine (Philips, iU22 xMATRIX, Philips Medical Systems, Bothell, WA, USA), oper-
ated at a Doppler gain of 76%, low persistence, pulse repetition frequency 500 Hz, and wall filter 47 Hz. The depth 
and position of the focus (single focus) were adapted based on the size of the tumour. The settings were standard-
ized and repeated at each imaging session. The plane with maximum vascular signals was found by slowly moving 
the probe over the tumour, both in longitudinal and transverse orientation. The colour window was reduced in 
size to just cover the tumour to improve the colour sensitivity and frame rate. Stable vascular images and movies 
were captured and stored for quantitative analyses and the scan plane was documented to enable future scanning 
at the identical location. During the CA4P infusion, PDUS was performed at the identical tumour location at 10, 
20 and 30 min. The PDUS examinations were repeated at 24 and 72 h PI at matched locations. At a later occasion, 
the captured images were retrieved and the boundary of the tumour was manually delineated on the computer 
with the use of the software Fiji®62. The density of the vascular signals within the demarcated tumour was then 
calculated and expressed as the VI (the number of vessels in demarcated tumour to total area of demarcated 
tumour) by a researcher blinded to patient identification and tumour treatment status.
Contrast-enhanced ultrasound imaging. As described in our previous study, to perform the CEUS, 
a MB contrast agent (Sonovue®, Bracco, Milan, Italy), consisting of lipid-stabilized MB’s with a sulphur hex-
afluoride gas core, was injected IV as a bolus (0.04 mL kg−1) immediately followed by a 2.5 mL flush of sterile 
saline (Mini-Plasco NaCl 0.9%, Braun, Diegem, Belgium)45. Images were acquired using a linear 12-5 MHz probe. 
Machine settings were standardized: gain optimized to start with a nearly black baseline image (suppression 
background signal), dynamic range 50, mechanical index 0.09, and persistence off. The depth and position of the 
focus (single focus) were adapted based on the size of the tumour. During pre-treatment scanning, the scan plane 
was recorded for future assessment. All dogs received three injections of contrast media. Based on pre-existing 
knowledge, the second and third injection results were used since they resulted in more consistent enhancement 
than the first injection63. Between injections, the output power was adjusted to maximum with continued imaging 
of the tumour until background echogenicity was similar to pre-injection levels, indicating destruction of most 
residual contrast bubbles. In our experience, complete wash-out of the MBs was accomplished within 120 s, there-
fore the time frame for data collection was set at 0–120 s.
After CA4P infusion, CEUS was repeated at a matched tumour location at 72 h PI. All CEUS studies were 
digitally registered as movie clips (10 frames/sec) for two min after bolus injection. Clips were then exported to 
an offline computer, where they were randomized and anonymized. Subsequently, the clips were analysed using 
integrated dedicated specialized computer software (VueBox®, Bracco Suisse, Geneva, Switzerland) for objective 
quantitative analysis. Per study, three tumour ROI (whole tumour, tumour periphery, and tumour centre) were 
drawn manually on the CEUS image (Fig. 3). The first ROI encompassed the entire tumour. Second, the analysis 
ROI of the tumour periphery was drawn to outline the outer one-third radius of the tumour. Finally, the analysis 
ROI of the tumour centre was manually drawn inside the two-thirds radius of the tumour. Subsequently, mean 
pixel intensities and time-intensity curves were created for each ROI. The curves were then analysed for perfusion 
parameters representing blood volume and blood velocity.
Histopathological analysis and immunohistochemistry. The tumour tissue samples were fixed 
in a 10% buffered formalin solution, embedded in paraffin, and sectioned at 4 μm. Per biopsy, four sections 
were cut at different depth within the biopsy to acquire technical replicate sections. Two sections with a 12 μm 
interstice were stained with Haematoxylin and Eosin (HE) for the histopathological evaluation of necrosis. 
For evaluation of the MVD, two sections with a 12 μm interstice were stained with the endothelial cell marker 
(vWF). Deparaffinized and hydrated sections underwent pre-treatment by 15 min incubation with Proteinase K 
S300402-2 (Agilent, Santa Clara, CA95051, USA) and subsequently by 5 min incubation with H2O2 solution to 
block the endogenous peroxidase activity. After rinsing, the sections were incubated with the primary antibody, 
i.e. polyclonal rabbit-anti human vWF antibody A0082 (Agilent, Santa Clara, CA95051, USA) was applied at 
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1:1600 dilution for 30 min at room temperature. Subsequently, HRP was linked to the primary antibodies using 
Envision Link Rabbit kit K401111-2 (Agilent, Santa Clara, CA95051, USA). Sections were then rinsed, incubated 
with 3,3′-diaminobenzidine solution, and counterstained with Haematoxylin.
Histological assessment of all biopsies was performed with the use of a Leica light microscope (Leica DMLB®, 
Leica Microsystems, Germany). Slides were first scanned at low power (×20) to identify tumoural tissue. Five 
fields within tumoural tissue per section were then selected randomly as counting frame at higher power (×100). 
Density measures were obtained by overlaying a grid on the counting frame and quantifying the crossing points 
that hit the area of interest, with the use of the Fiji® software. In every HE-stained section, the relative amount 
of necrotic tumour tissue was expressed as the ratio of necrotic tumour tissue to the total tumour area. The 
averages of the five ratios were then calculated for each tumour biopsy. Microvessel counts were calculated in 
every vWF-stained section, based on the total number of vWF-positive structures within the tumour area and 
expressed as the MVD (ratio of tumour blood vessels mm−2 of tumour tissue). The averages of the five MVDs 
were then calculated for each tumour biopsy. Only uninterrupted round vWF-positive structures containing a 
lumen were counted as microvessels. Larger vessels with thick muscular walls and vessels with a lumen greater 
than approximately eight red blood cells were excluded, as suggested by Bosari and colleagues64. All measure-
ments were performed blinded to patient identification and tumour treatment status. To facilitate recognition of 
vWF-positive structures, a H-DAB filter was applied within the FiJi® software. Figure 8 shows a representative 
case of MVD counting.
Statistical analysis. The statistical analyses were performed as described previously45. Except for the histo-
logical data, all data were analysed with nonparametric paired tests due to the non-normal distribution of the data 
using R (version 3.4.1). The Wilcoxon signed rank test and Friedman’s test (package stats, version 3.3.1) were used 
for comparing paired samples across two or more time points respectively. The Mack-Skilling’s test was used as 
replicated measures variant of the Friedman’s test accounting for multiple replicates per sample in the CEU data 
(package asbio, version 1.5). Post hoc analysis of Friedman’s tests was performed using Wilcoxon signed rank tests 
and all p-values were corrected using the Holm-Bonferroni method (package stats, version 3.3.1). A two-sided 
p-value of ≤0.05 was considered to indicate statistical significance.
Also the histological data, i.e. necrosis and blood vessel density data, were analysed as described in our previous 
study45, using generalized linear mixed models to account for variability of individual patients and biopsies using 
random effects. The package lme4 (version 1.1) was used in R (version 3.4.1). Given evidence of overdispersion, neg-
ative binomial generalized linear mixed models were fitted with the number of blood vessels or the necrosis surface 
as an outcome, treatment as a fixed effect, along with a random intercept and random slope to allow for differences in 
treatment effect between individual patients and control for correlation among replicated measurements. An offset 
was added to control the reference area of tumour tissue assessed in each counting frame.
The Pearson correlation coefficient was calculated and evaluated for statistical significance (package stats, 
version 3.3.1) to examine the correlation between PDUS and the MVD, and between the individual CEUS param-
eters and the MVD.
Ethics approval and consent to participate. The study protocol adhered to the European Communities 
Council Directive (86/609/EEC)/principles of laboratory animal care (NIH publication No. 85-23, revised 1985). 
Approval was obtained from the local research Ethical Committee (Approval No. EC2015/143 and EC2016/66) of 
the Faculty of Veterinary Medicine of Ghent University, Belgium and from the Deontological Committee of the 
Federal Public Service of Health, Food Chain Safety and Environment, Belgium. Written informed consent was 
obtained from all patient owners before entry into the study. The use of CA4P in canine patients was approved 
(approval number 0002588) by the Belgian Federal Agency for Medicines and Health Products (FAMHP).
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on rea-
sonable request.
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